Study | Country | Histology | Follow-up (months) | Stage | Chemotherapy regimen | CRT alone | CRT + surgery | Surgery type |
---|---|---|---|---|---|---|---|---|
Mazeron (2016) [17] | France | Squamous/Adenocarcinoma/Adenosquamous | 39.3–75.5 | IB1 | Cisplatin /Carboplatin | 157 | 54 | Radical hysterectomy |
IB2 | ||||||||
IIA2 | ||||||||
IIB | ||||||||
Fanfani (2016) [18] | Italy | Squamous/Adenocarcinoma | CRT: 14–127 CRT+ Surgery: 13–210 | IIIA | Cisplatin | 77 | 73 | Radical hysterectomy |
IIIB | ||||||||
Cetina (2013) [16] | Mexico | Squamous/Adenocarcinoma/Adenosquamous | 3–80 | IB2 | Cisplatin and Gemcitabine | 100 | 111 | Radical hysterectomy |
IIA2 | ||||||||
IIB | ||||||||
Leguevaque (2011) [12] | France | Squamous/Adenocarcinoma | CRT: 5–64 CRT+ Surgery: 5–134 | IB1 | Cisplatin | 44 | 67 | Piver II extended/extrafascial hysterectomy |
IB2 | ||||||||
IIA | ||||||||
IIA2 | ||||||||
IIB | ||||||||
IIIA | ||||||||
IIIB | ||||||||
IVA | ||||||||
Keys (2003) [13] | U.S.A. | Squamous/Adenocarcinoma/Adenosquamous | 3.6–193.2 | IB2 | Cisplatin | 124 | 132 | Extrafascial hysterectomy |
Morice (2012) [15] | France | Squamous/Adenocarcinoma | 4.8–69.6 | IB2 | Cisplatin | 30 | 31 | Laparoscopic/radical hysterectomy |
IIA | ||||||||
IIB | ||||||||
Darus (2008) [19] | U.S.A. | Squamous/Adenocarcinoma/Adenosquamous | 1.5–138 | IB2 | Cisplatin, 5FU of capecitabine | 30 | 24 | Extrafascial hysterectomy |
Perez (1995) [14] | U.S.A. | Epidermoid/Adenocarcinoma/Adenosquamous | 36–276 | IB | no | 895 | 227 | Exploratory laparotomy |
IIA | ||||||||
IIB |